机构：[1]Department of Gastroenterology, The Shanghai Tenth People’s Hospital, Department of Bioinformatics, School of Life Sciences and Technology, Tongji University, Shanghai, China,[2]Division of Digestive Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, United States,[3]Center for IBD Research, Department of Gastroenterology, The Shanghai Tenth People’s Hospital, Tongji University, Shanghai, China,[4]State Key Laboratory of Oncogenes and Related Genes, Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China,[5]Department of Gastroenterology, First Affiliated Hospital of Kunming Medical University, Yunnan Institute of Digestive Diseases, Kunming, China,昆明医科大学附属第一医院[6]Department of Gastroenterology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China,[7]Guangdong Institute of Gastroenterology, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
第一作者机构：[1]Department of Gastroenterology, The Shanghai Tenth People’s Hospital, Department of Bioinformatics, School of Life Sciences and Technology, Tongji University, Shanghai, China,
通讯作者：
推荐引用方式(GB/T 7714)：
Zhu Ruixin,He Peijian,Liu Zhanju,et al.Editorial: Microbiome in IBD: From Composition to Therapy[J].FRONTIERS IN PHARMACOLOGY.2021,12:doi:10.3389/fphar.2021.721992.
APA：
Zhu, Ruixin,He, Peijian,Liu, Zhanju,Liu, Ningning,Miao, Yinglei...&Zhu, Lixin.(2021).Editorial: Microbiome in IBD: From Composition to Therapy.FRONTIERS IN PHARMACOLOGY,12,
MLA：
Zhu, Ruixin,et al."Editorial: Microbiome in IBD: From Composition to Therapy".FRONTIERS IN PHARMACOLOGY 12.(2021)
